Table of Contents Author Guidelines Submit a Manuscript
Parkinson’s Disease
Volume 2012, Article ID 128356, 6 pages
http://dx.doi.org/10.1155/2012/128356
Review Article

Genetic Rat Models of Parkinson's Disease

1Field Neurosciences Institute, Laboratory for Restorative Neurology, Department of Psychology, Central Michigan University, Mt. Pleasant, MI 48859, USA
2Field Neurosciences Institute, Laboratory for Restorative Neurology, Program in Neuroscience, Central Michigan University, Mt. Pleasant, MI 48859, USA
3Field Neurosciences Institute, Laboratory for Restorative Neurology, Department of Psychology and Program in Neuroscience, College of Medicine, Central Michigan University, Mt. Pleasant, MI 48859, USA
4Field Neurosciences Institute, St. Mary's of Michigan, Saginaw MI 48604, USA

Received 10 December 2011; Accepted 20 January 2012

Academic Editor: Kah-Leong LIM

Copyright © 2012 Ryan M. Welchko et al. This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

Linked References

  1. T. M. Dawson, “New animal models for Parkinson's disease,” Cell, vol. 101, no. 2, pp. 115–118, 2000. View at Publisher · View at Google Scholar · View at Scopus
  2. M. G. Spillantini, M. L. Schmidt, V. M. Y. Lee, J. Q. Trojanowski, R. Jakes, and M. Goedert, “α-synuclein in Lewy bodies,” Nature, vol. 388, no. 6645, pp. 839–840, 1997. View at Publisher · View at Google Scholar · View at Scopus
  3. O. Cooper, P. Hallett, and O. Isacson, “Using stem cells and iPS cells to discover new treatments for Parkinson's disease,” Parkinsonism & Related Disorders, vol. 18, supplement 1, pp. S14–S16, 2012. View at Google Scholar
  4. M. Yamada, Y. Mizuno, and H. Mochizuki, “Parkin gene therapy for α-synucleinopathy: a rat model of Parkinson's disease,” Human Gene Therapy, vol. 16, no. 2, pp. 262–270, 2005. View at Publisher · View at Google Scholar · View at Scopus
  5. R. Jakes, M. G. Spillantini, and M. Goedert, “Identification of two distinct synucleins from human brain,” FEBS Letters, vol. 345, no. 1, pp. 27–32, 1994. View at Publisher · View at Google Scholar · View at Scopus
  6. M. H. Polymeropoulos, J. J. Higgins, L. I. Golbe et al., “Mapping of a gene for Parkinson's disease to chromosome 4q21-q23,” Science, vol. 274, no. 5290, pp. 1197–1199, 1996. View at Publisher · View at Google Scholar · View at Scopus
  7. M. H. Polymeropoulos, C. Lavedan, E. Leroy et al., “Mutation in the α-synuclein gene identified in families with Parkinson's disease,” Science, vol. 276, no. 5321, pp. 2045–2047, 1997. View at Publisher · View at Google Scholar · View at Scopus
  8. J. J. Zarranz, J. Alegre, J. C. Gómez-Esteban et al., “The new mutation, E46K, of α-synuclein causes Parkinson and Lewy body dementia,” Annals of Neurology, vol. 55, no. 2, pp. 164–173, 2004. View at Publisher · View at Google Scholar · View at Scopus
  9. R. Krüger, W. Kuhn, T. Müller et al., “Ala30Pro mutation in the gene encoding α-synuclein in Parkinson's disease,” Nature Genetics, vol. 18, no. 2, pp. 106–108, 1998. View at Google Scholar · View at Scopus
  10. R. G. Perez, J. C. Waymire, E. Lin, J. J. Liu, F. Guo, and M. J. Zigmond, “A role for α-synuclein in the regulation of dopamine biosynthesis,” Journal of Neuroscience, vol. 22, no. 8, pp. 3090–3099, 2002. View at Google Scholar · View at Scopus
  11. F. J. S. Lee, F. Liu, Z. B. Pristupa, and H. B. Niznik, “Direct binding and functional coupling of α-synuclein to the dopamine transporters accelerate dopamine-induced apoptosis,” FASEB Journal, vol. 15, no. 6, pp. 916–926, 2001. View at Publisher · View at Google Scholar · View at Scopus
  12. D. Kirik, C. Rosenblad, C. Burger et al., “Parkinson-like neurodegeneration induced by targeted overexpression of α-synuclein in the nigrostriatal system,” Journal of Neuroscience, vol. 22, no. 7, pp. 2780–2791, 2002. View at Google Scholar · View at Scopus
  13. R. L. Klein, M. A. King, M. E. Hamby, and E. M. Meyer, “Dopaminergic cell loss induced by human A30P α-synuclein gene transfer to the rat substantia nigra,” Human Gene Therapy, vol. 13, no. 5, pp. 605–612, 2002. View at Publisher · View at Google Scholar · View at Scopus
  14. C. Lo Bianco, J. L. Ridet, B. L. Schneider, N. Déglon, and P. Aebischer, “α-synucleinopathy and selective dopaminergic neuron loss in a rat lentiviral-based model of Parkinson's disease,” Proceedings of the National Academy of Sciences of the United States of America, vol. 99, no. 16, pp. 10813–10818, 2002. View at Publisher · View at Google Scholar · View at Scopus
  15. M. Yamada, T. Iwatsubo, Y. Mizuno, and H. Mochizuki, “Overexpression of α-synuclein in rat substantia nigra results in loss of dopaminergic neurons, phosphorylation of α-synuclein and activation of caspase-9: Resemblance to pathogenetic changes in Parkinson's disease,” Journal of Neurochemistry, vol. 91, no. 2, pp. 451–461, 2004. View at Publisher · View at Google Scholar · View at Scopus
  16. O. S. Gorbatyuk, S. Li, L. F. Sullivan et al., “The phosphorylation state of Ser-129 in human α-synuclein determines neurodegeneration in a rat model of Parkinson disease,” Proceedings of the National Academy of Sciences of the United States of America, vol. 105, no. 2, pp. 763–768, 2008. View at Publisher · View at Google Scholar · View at Scopus
  17. S. A. da Silveira, B. L. Schneider, C. Cifuentes-Diaz et al., “Phosphorylation does not prompt, nor prevent, the formation of α-synuclein toxic species in a rat model of Parkinson's disease,” Human Molecular Genetics, vol. 18, no. 5, pp. 872–887, 2009. View at Publisher · View at Google Scholar · View at Scopus
  18. A. Recchia, D. Rota, P. Debetto et al., “Generation of a α-synuclein-based rat model of Parkinson's disease,” Neurobiology of Disease, vol. 30, no. 1, pp. 8–18, 2008. View at Publisher · View at Google Scholar · View at Scopus
  19. F. Lelan, L. Lescaudron, C. Boyer et al., “Effects of human alpha-synuclein A53T-A30P mutations on SVZ and local olfactory bulb cell proliferation in a transgenic rat model of Parkinson disease,” Parkinson's Disease, vol. 2011, Article ID 987084, 11 pages, 2011. View at Publisher · View at Google Scholar
  20. J. Dusonchet, O. Kochubey, K. Stafa et al., “A rat model of progressive nigral neurodegeneration induced by the Parkinson's disease-associated G2019S mutation in LRRK2,” Journal of Neuroscience, vol. 31, no. 3, pp. 907–912, 2011. View at Publisher · View at Google Scholar
  21. H. Zhou, C. Huang, J. Tong, W. C. Hong, Y. -J. Liu, and X. -G. Xia, “Temporal expression of mutant LRRK2 in adult rats impairs dopamine reuptake,” International Journal of Biological Sciences, vol. 7, no. 6, pp. 753–761, 2011. View at Google Scholar
  22. V. Sanchez-Guajardo, F. Febbraro, D. Kirik, and M. Romero-Ramos, “Microglia acquire distinct activation profiles depending on the degree of α-synuclein neuropathology in a rAAV based model of Parkinson's disease,” PLoS One, vol. 5, no. 1, Article ID e8784, 2010. View at Publisher · View at Google Scholar · View at Scopus
  23. C. Lo Bianco, N. Déglon, W. Pralong, and P. Aebischer, “Lentiviral nigral delivery of GDNF does not prevent neurodegeneration in a genetic rat model of Parkinson's disease,” Neurobiology of Disease, vol. 17, no. 2, pp. 283–289, 2004. View at Publisher · View at Google Scholar · View at Scopus
  24. M. Decressac, A. Ulusoy, B. Mattsson et al., “GDNF fails to exert neuroprotection in a rat α-synuclein model of Parkinson's disease,” Brain, vol. 134, no. 8, pp. 2302–2311, 2011. View at Publisher · View at Google Scholar
  25. C. Lo Bianco, B. L. Schneider, M. Bauer et al., “Lentiviral vector delivery of parkin prevents dopaminergic degeneration in an α-synuclein rat model of Parkinson's disease,” Proceedings of the National Academy of Sciences of the United States of America, vol. 101, no. 50, pp. 17510–17515, 2004. View at Publisher · View at Google Scholar · View at Scopus
  26. T. Kitada, S. Asakawa, N. Hattori et al., “Mutations in the parkin gene cause autosomal recessive juvenile parkinsonism,” Nature, vol. 392, no. 6676, pp. 605–608, 1998. View at Publisher · View at Google Scholar · View at Scopus
  27. J. P. Taylor, I. F. Mata, and M. J. Farrer, “LRRK2: a common pathway for parkinsonism, pathogenesis and prevention?” Trends in Molecular Medicine, vol. 12, no. 2, pp. 76–82, 2006. View at Publisher · View at Google Scholar · View at Scopus
  28. I. F. Mata, O. A. Ross, J. Kachergus et al., “LRRK2 mutations are a common cause of Parkinson's disease in Spain,” European Journal of Neurology, vol. 13, no. 4, pp. 391–394, 2006. View at Publisher · View at Google Scholar · View at Scopus